CAM
TARA icon

Cormorant Asset Management’s Protara Therapeutics TARA Stock Holding History

Cormorant Asset Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-350,000
Closed -$5.51M – 124
2021
Q1 		$5.51M Hold
350,000
– – 0.12% 90
2020
Q4 		$8.47M Sell
350,000
-100,000
-22% -$2.16M 0.2% 73
2020
Q3 		$7.57M Buy
+450,000
New +$10.4M 0.29% 65

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cormorant Asset Management's TARA Position: Q2 2021 in Review

Cormorant Asset Management sold out of Protara Therapeutics (TARA) in Q2 2021, closing a stake of 350,000 shares — an estimated $5.51M sold.

Cormorant Asset Management first reported a position in TARA in Q3 2020 and held it in 3 quarters. The position peaked at $8.47M in Q4 2020. 41 funds tracked by Wall St. Rank hold TARA as of Q2 2021.

  • Cormorant Asset Management reported no remaining Protara Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 350,000 Protara Therapeutics shares in Q2 2021, an estimated $5.51M.
  • Cormorant Asset Management first reported a position in Protara Therapeutics in Q3 2020 and held it in 3 quarters.
  • Cormorant Asset Management's Protara Therapeutics position peaked at $8.47M in Q4 2020.
  • 41 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.